Note: You are reading this message either because your browser is not standards-compliant, or your browser failed to load our css files.

Covered Companies

Cel-Sci Corporation - CVM

The WHO (I'm not kidding- World Health Organization) has officially declared the Swine Flu as a world wide pandemic. This past week, the WHO raised the Swine Flu to "Phase 6", it's highest level for global risk. The Phase 6 alert does not mean the severity is increasing- it means the spread is more global. The Phase 6 ranking opens the door to accelerated production and research on a number of possible therapies and vaccines.

One company getting major recognition for a possible therapy is AMEX listed Cel-Sci (AMEX: CVM), a stock I have been following on and off for many years. Last week, CVM announced its L.E.A.P.S (Ligand Epitope Antigen Presentation System) technology, could represent an immune based therapy for swine flu, and had shown promise. At the Naval Medical Research Center in Silver Spring, MD, L.E.A.P.S has demonstrated an ability to enhance the body's natural protection against many different kinds of diseases. The Navy is focused on using the therapy to treat Malaria. This past week, Cel-Sci announced it was developing an immune based treatment for the Swine Flu, and the stock went absolutely ballistic.

Cel-Sci traded 32 million shares in one day last week, the highest volume in its more than 20 years of being a publicly traded company under the ticker CVM. CVM also surged from about $.25 to $.80 in one day. Pretty crazy.

Cel-Sci Corporation
Cel-Sci Corporation (CVM)
http://www.cel-sci.com/
Coverage: June 13, 2009 - December 13, 2009
Featured: June 13, 2009

Latest Newsletter Editions

spacer
Sat, Jan 16, 2010 @ 09:01 am
The Biotech Buzz Rerun I looked for some recent small stock biotech winners. Check out the action in ECTE of late. $1.30 to $2.20 this month on increasing volume as the stock climbs the charts. There's a lot of action in these small biotechs right now. Do you believe in reincarnation? In the stock market...
Wed, Jan 13, 2010 @ 11:01 am
The China/Biotech Buzz It's been a very strong week for my China ideas, with several of the top choices delivering strong news and making new all time highs this week. Review and comments on the hot China ideas below. Biotechs are buzzing right now, and a great number of small cap/biotech stocks are...
Wed, Dec 2, 2009 @ 08:12 am
Coming Attractions You might recall an edition I published about a month ago suggesting it was time to step back, take a look at every idea, and set some cash aside to get past tax selling season and into December. The time has come. I suspect December will be a good month in the markets. Small stocks...
Mon, Nov 9, 2009 @ 02:11 pm
You Asked For It; You'll Get It As expected, lots of you read about my Interclick (NASDAQ: ICLK) idea over the weekend, and sent me the same comment: Why didn't you tell us about this one back in May when it was still under $1 on the Bulletin Board? Point taken- after all, isn't that the goal of investing...
Sat, Oct 10, 2009 @ 04:10 pm
A Couple More Updates: Cel-Sci (AMEX: CVM) and CalAmp (NASDAQ: CAMP) There's lots more action to cover from this past week, so let's get to two more of the actively traded ideas I have shared of late. Cel-Sci (NYSE AMEX: CVM): The Squawking and Finger Pointing Was Inevitable CVM, one of the hottest...

Click Here For More Newsletters on CVM

spacer

Latest Blog Entries

spacer
Thu, Sep 10, 2009 @ 09:35 am
Here I am again, trapped between my trader-self (which wants to take a profit on the bird in the hand) and my investor-self (which is eying the two birds in the bush). The source of my conflict is CEL-SCI (CVM) of course… which is up about 111% since we bought it back in June, and [...]
Wed, Jun 24, 2009 @ 04:28 pm
A new item of interest on Cel-Sci Corp. (AMEX: CVM) hit the wires today, and I wanted to address it and the subsequent move in the stock. The company plans to raise $5 million in much-needed funds from an institutional investor to speed up work on its swine-flu treatment and also to “validate” its $15 million [...]

Quote Data

spacer
Last Trade: 0.69 Bid: 0.0000
Last Size: 0 Ask: 0.0000
Trade Time: 4:00pm Bid x Ask Size: N/A
Change: down arrow -0.0060 (-0.86%) Day's Range: 0.68 - 0.71
Prev Close: 0.6960 52wk Range: 0.20 - 2.10
Open: 0.6800 P/E (ttm): N/A
Volume: 920,618 EPS (ttm): -0.228
spacer
[Chart]

Business Summary

spacer
CEL-SCI Corporation, a biotechnology company, engages in research and development of drugs and vaccines for the treatment of cancer and infectious diseases. The company’s primary product Multikine is a patented immunotherapeutic agent consisting of a mixture of naturally occurring cytokines under phase II clinical trail for the treatment of cancer. It also develops CEL-1000 peptide product with its Ligand Epitope Antigen Presentation System technology which is under preclinical stage for the protection/treatment of animals against herpes, malaria, viral encephalitis, and cancer. The company markets its products to cancer centers, physicians, and clinics involved in immunotherapy. CEL-SCI was founded in 1983 and is based in Vienna, Virginia.

Disclosure

spacer
TGR Group LLC, an affiliate of MarketByte LLC, has been paid a fee of 100,000 newly issued restricted shares by Cel-Sci Corporation, for coverage of the Company.

Recent News Headlines

spacer
Fri, 12 Mar 2010 21:46:27 Etc/GMT
Fri, 12 Mar 2010 12:00:00 Etc/GMT
Wed, 10 Mar 2010 15:30:00 Etc/GMT
CEL-SCI Corporation announced today that it has received a $125,000 payment from Byron Biopharma under its licensing agreement where CEL-SCI granted Byron an exclusive license to market and distribute the Company's cancer drug Multikine® in the Republic of South Africa .
Mon, 22 Feb 2010 14:45:00 Etc/GMT
CEL-SCI Corporation and their scientific collaborators announced today that the Company's CEL-2000 vaccine demonstrated that it is able to block the progression of rheumatoid arthritis in a mouse model.  The results were published in the scientific peer-reviewed Journal of International Immunopharmacology in an article titled "CEL-2000: A Therapeutic Vaccine for Rheumatoid Arthritis Arrests Disease Development and Alters Serum Cytokine / Chemokine Patterns in the Bovine Collagen Type II Induced Arthritis  in the DBA Mouse Model" with lead author Dr.
Fri, 19 Feb 2010 18:04:33 Etc/GMT
Thu, 18 Feb 2010 14:00:00 Etc/GMT
Wed, 17 Feb 2010 20:22:44 Etc/GMT
Wed, 17 Feb 2010 14:00:00 Etc/GMT
Tue, 16 Feb 2010 17:05:15 Etc/GMT
Tue, 16 Feb 2010 14:00:00 Etc/GMT
CEL-SCI Corporation reports financial results for the quarter ended December 31, 2009.
Fri, 12 Feb 2010 22:16:36 Etc/GMT
Thu, 11 Feb 2010 11:36:55 Etc/GMT
Thu, 11 Feb 2010 11:36:55 Etc/GMT
Thu, 11 Feb 2010 11:32:20 Etc/GMT
Wed, 10 Feb 2010 11:11:30 Etc/GMT
Wed, 10 Feb 2010 11:11:30 Etc/GMT
Wed, 3 Feb 2010 14:00:00 Etc/GMT
CEL-SCI Corporation announced that Geert Kersten, Chief Executive Officer, will be presenting at the 2010 BIO CEO & Investor Conference.  Hosted by the Biotechnology Industry Organization , the conference will take place February 8-9 at the Waldorf=Astoria in New York.
Mon, 1 Feb 2010 11:01:31 Etc/GMT
Fri, 29 Jan 2010 22:28:46 Etc/GMT
Mon, 25 Jan 2010 13:30:00 Etc/GMT

China Energy Recovery, Inc.
Share
Market Summary
Dow 10685.98 +43.83 (+0.41%)
Nasdaq 2378.01 +15.80 (+0.67%)
Russell 2K 679.58 +5.17 (+0.77%)
S&P 500 1159.46 +8.95 (+0.78%)
S&P 100 529.97 +3.58 (+0.68%)
Quotes are delayed 20 minutes.

Add to Google

China Stocks and Penny Stocks - Discover Tomorrow's Winners Today

© 2010 OTC Journal